OncoMatch/Clinical Trials/NCT06973187
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Is NCT06973187 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including BGB-16673 and Pirtobrutinib for chronic lymphocytic leukemia.
Treatment: BGB-16673 · Pirtobrutinib — The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Must have received: covalent bruton tyrosine kinase inhibitor
Cannot have received: bruton tyrosine kinase protein degrader
Cannot have received: noncovalent bruton tyrosine kinase inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Phoenix · Phoenix, Arizona
- University of California San Diego (Ucsd) Moores Cancer Center · La Jolla, California
- UCLA Department of Medicine Hematologyoncology · Los Angeles, California
- Stanford Cancer Institute · Palo Alto, California
- Christiana Care · Newark, Delaware
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify